Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NT5E | P21589 | 18/20 | 0.58 |
| ▸ | CTSL | P07711 | 1/20 | 0.46 |
| ▸ | CTSS | P25774 | 1/20 | 0.46 |
| ▸ | CTSK | P43235 | 1/20 | 0.46 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.44 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21839511 | 0.98 | NT5E (0.59) | NT5ECTSLCTSSCTSKTAS1R3 | |
| SCHEMBL21839696 | 0.98 | NT5E (0.58) | NT5ECTSLCTSSCTSKTAS1R3 | |
| SCHEMBL21839681 | 0.94 | NT5E (0.54) | NT5E | |
| SCHEMBL21839648 | 0.92 | NT5E (0.59) | NT5ETAS1R3TAS1R1 | |
| SCHEMBL21839751 | 0.92 | NT5E (0.51) | NT5E | |
| SCHEMBL21839588 | 0.90 | NT5E (0.57) | NT5E | |
| SCHEMBL21839824 | 0.89 | NT5E (0.57) | NT5ETAS1R3TAS1R1 | |
| SCHEMBL21839837 | 0.89 | NT5E (0.56) | NT5ETAS1R3TAS1R1 | |
| SCHEMBL21839805 | 0.89 | NT5E (0.74) | NT5E | |
| SCHEMBL21839603 | 0.88 | NT5E (0.62) | NT5ETAS1R3TAS1R1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11591355-B2 | CD73 inhibitors and uses thereof | PELOTON THERAPEUTICS INC. (US) | 2023-02-28 | — | — | US | disclosed |
| US-11591355-B2 | CD73 inhibitors and uses thereof | PELOTON THERAPEUTICS INC. (US) | 2023-02-28 | — | — | US | disclosed |
| US-20210317150-A1 | CD73 INHIBITORS AND USES THEREOF | PELOTON THERAPEUTICS, INC. (US) | 2021-10-14 | — | — | US | disclosed |
| US-20210317150-A1 | CD73 INHIBITORS AND USES THEREOF | PELOTON THERAPEUTICS, INC. (US) | 2021-10-14 | — | — | US | disclosed |
| US-20200115404-A1 | CD73 INHIBITORS AND USES THEREOF | PELOTON THERAPEUTICS INC. | 2020-04-16 | — | — | US | disclosed |
| US-20200115404-A1 | CD73 INHIBITORS AND USES THEREOF | PELOTON THERAPEUTICS INC. | 2020-04-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200115404-A1 | CD73 INHIBITORS AND USES THEREOF | ENTPD5, ENTPD1, NT5E | NT5E 3/4885CTSL 1251/4885CTSS 854/4885 |
| US-11591355-B2 | CD73 inhibitors and uses thereof | ENTPD5, ENTPD1, ENTPD3 | NT5E 5/4885CTSL 1567/4885CTSS 965/4885 |
| US-20210317150-A1 | CD73 INHIBITORS AND USES THEREOF | ENTPD5, ENTPD1, NT5E | NT5E 3/4885CTSL 1251/4885CTSS 854/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.